Five months after immunization, two doses of the Pfizer-BioNTech vaccine appeared to offer virtually no defense against moderate illness caused by the omicron variant — as measured by visits to emergency departments and urgent care clinics — among adolescents aged 12 to 17 years, according to data published on Tuesday by the Centers for Disease Control and Prevention.
But booster shots dramatically increased the protection, lending support to the agency’s recommendation of booster shots for everyone 12 and older.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
We humbly apologize for the inconvenience.